NR6A1 and prostate cancer: In addition, our data also suggested that the siRNA-mediated down-regulation of NR6A1 expression in prostate cancer cells of DU145 and PC3 could reverse the epithelial phenotype and repress a mesenchymal phenotype, and overexpression of NR6A1 in 22RV1 could promote EMT progression.